首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

1609740

2025-2033 年日本細胞和基因療法市場報告（按治療類型、適應症、交付模式、最終用戶和地區分類）

Japan Cell and Gene Therapy Market Report by Therapy Type, Indication, Delivery Mode, End User, and Region 2025-2033

出版日期: 2024年12月05日 | 出版商:

IMARC | 英文 121 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024 年，日本細胞和基因療法市場規模達到 7.27IMARC Group美元。慢性病和遺傳疾病的日益普及正在推動對能夠解決這些醫療保健挑戰的先進療法的需求，這主要推動了市場的成長。

細胞和基因療法是尖端的醫學方法，為治療各種疾病和病症帶來了巨大的希望。本質上，細胞療法涉及移植或操縱活細胞來替換或修復體內受損或故障的組織。這可以包括使用幹細胞來再生受損的器官或組織。另一方面，基因治療則著重於修改或糾正導致疾病的錯誤基因。這可以透過在患者細胞內引入、替換或修復特定基因來實現。細胞和基因療法都處於個人化醫療的前沿，提供了提供有針對性的個人化治療的潛力，可以解決疾病的根本原因，而不僅僅是控制症狀。這些創新療法在臨床試驗中取得了顯著的成功，並為醫療保健的新時代鋪平了道路，有可能徹底改變遺傳性疾病、癌症和其他一系列具有挑戰性的醫療狀況的治療。

日本細胞和基因治療市場趨勢：

日本細胞和基因療法市場正在迅速崛起，成為該國醫療保健領域一個充滿活力且前景光明的領域。隨著人口老化和慢性病負擔的日益加重，對能夠提供長期解決方案的創新療法的需求不斷增加。細胞和基因療法因其解決未滿足的醫療需求的潛力而在日本獲得了極大的關注和投資。日本研究人員和生物製藥公司一直積極致力於利用這些尖端技術開發新療法。日本監管機構也採取措施促進細胞和基因療法的臨床開發和商業化，使其成為對國內和國際參與者有吸引力的市場。學術界、工業界和醫療保健提供者之間的合作以及精準醫療方法的日益採用進一步推動了市場的成長。因此，日本細胞和基因治療市場有望持續擴張，並可能在該國未來的醫療保健中發揮關鍵作用。

日本細胞和基因治療市場細分：

治療類型見解：

細胞療法
幹細胞
非幹細胞
基因治療

指示見解：

心血管疾病
腫瘤疾病
遺傳性疾病
傳染病
神經系統疾病
其他

交付模式見解：

體內
離體

最終使用者見解：

醫院
癌症護理中心
製藥和生物技術公司
其他

競爭格局：

市場研究報告也對競爭格局進行了全面分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀表板和公司評估象限等競爭分析。此外，也提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

到目前為止，日本細胞和基因治療市場的表現如何，未來幾年將如何表現？
COVID-19 對日本細胞和基因治療市場有何影響？
日本細胞和基因治療市場按治療類型分類是怎樣的？
根據適應症，日本細胞和基因治療市場的詳細情形如何？
日本細胞和基因療法市場在交付模式方面的詳細情形如何？
日本細胞和基因治療市場的最終用戶詳細情形如何？
日本細胞和基因治療市場價值鏈的各個階段是什麼？
日本細胞和基因治療的關鍵促進因素和挑戰是什麼？
日本細胞和基因治療市場的結構如何？
日本細胞和基因治療市場的競爭程度如何？

本報告回答的關鍵問題：

日本細胞和基因治療市場迄今表現如何，未來幾年將如何表現？
COVID-19 對日本細胞和基因治療市場有何影響？
日本細胞和基因治療市場按治療類型分類是怎樣的？
根據適應症，日本細胞和基因治療市場的詳細情形如何？
日本細胞和基因療法市場在交付模式方面的詳細情形如何？
日本細胞和基因治療市場的最終用戶詳細情形如何？
日本細胞和基因治療市場價值鏈的各個階段是什麼？
日本細胞和基因治療的關鍵促進因素和挑戰是什麼？
日本細胞和基因治療市場的結構如何？
日本細胞和基因治療市場的競爭程度如何？

心血管疾病
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
腫瘤疾病
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
遺傳性疾病
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
傳染病
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
神經系統疾病
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
其他
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）

第 8 章：日本細胞和基因治療市場 - 細分：按交付模式

體內
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
離體
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）

第 9 章：日本細胞和基因治療市場 - 細分：按最終用戶分類

醫院
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
癌症護理中心
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
製藥和生物技術公司
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
其他
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）

第 10 章：日本細胞與基因療法市場 - 競爭格局

概述
市場結構
市場參與者定位
最佳制勝策略
競爭儀表板
公司評估象限

第 11 章：關鍵參與者簡介

Company A

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company B

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company C

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company D

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company E

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

第 12 章：日本細胞與基因治療市場 - 產業分析

促進因素、限制因素和機會
- 概述
- 促進要素
- 限制
- 機會
波特五力分析
- 概述
- 買家的議價能力
- 供應商的議價能力
- 競爭程度
- 新進入者的威脅
- 替代品的威脅
價值鏈分析

第 13 章：附錄

簡介目錄

Product Code: SR112024A17931

Japan cell and gene therapy market size reached USD 727 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,016 Million by 2033, exhibiting a growth rate (CAGR) of 12% during 2025-2033. The increasing adoption of chronic and genetic diseases is propelling the demand for advanced therapies capable of addressing these healthcare challenges, which is primarily driving the market growth.

Cell and gene therapy are cutting-edge medical approaches that hold immense promise for the treatment of various diseases and conditions. In essence, cell therapy involves the transplantation or manipulation of living cells to replace or repair damaged or malfunctioning tissues within the body. This can include the use of stem cells to regenerate damaged organs or tissues. On the other hand, gene therapy focuses on modifying or correcting faulty genes responsible for causing diseases. This can be achieved by introducing, replacing, or repairing specific genes within a patient's cells. Both cell and gene therapy are at the forefront of personalized medicine, offering the potential to provide targeted, individualized treatments that can address the root causes of diseases, rather than just managing their symptoms. These innovative therapies have shown remarkable success in clinical trials and are paving the way for a new era in healthcare, with the potential to revolutionize the treatment of genetic disorders, cancer, and a range of other challenging medical conditions.

Japan Cell and Gene Therapy Market Trends:

The Japan cell and gene therapy market is rapidly emerging as a dynamic and promising sector within the country's healthcare landscape. With an aging population and a growing burden of chronic diseases, there is a heightened demand for innovative treatments that can offer long-term solutions. Cell and gene therapy have gained significant attention and investment in Japan due to their potential to address unmet medical needs. Japanese researchers and biopharmaceutical companies have been actively engaged in developing novel therapies using these cutting-edge technologies. Regulatory authorities in Japan have also taken steps to facilitate the clinical development and commercialization of cell and gene therapies, making it an attractive market for both domestic and international players. The market's growth is further fueled by collaborations between academia, industry, and healthcare providers, as well as the increasing adoption of precision medicine approaches. As a result, the Japan cell and gene therapy market is poised for continued expansion and is likely to play a pivotal role in the future of healthcare in the country.

Japan Cell and Gene Therapy Market Segmentation:

Therapy Type Insights:

Cell Therapy
Stem Cell
Non-Stem Cell
Gene Therapy

Indication Insights:

Cardiovascular Disease
Oncology Disorder
Genetic Disorder
Infectious Disease
Neurological Disorder
Others

Delivery Mode Insights:

In-Vivo
Ex-Vivo

End User Insights:

Hospitals
Cancer Care Centers
Pharmaceutical and Biotechnology Companies
Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan cell and gene therapy market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan cell and gene therapy market?
What is the breakup of the Japan cell and gene therapy market on the basis of therapy type?
What is the breakup of the Japan cell and gene therapy market on the basis of indication?
What is the breakup of the Japan cell and gene therapy market on the basis of delivery mode?
What is the breakup of the Japan cell and gene therapy market on the basis of end user?
What are the various stages in the value chain of the Japan cell and gene therapy market?
What are the key driving factors and challenges in the Japan cell and gene therapy?
What is the structure of the Japan cell and gene therapy market and who are the key players?
What is the degree of competition in the Japan cell and gene therapy market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cell and Gene Therapy Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Cell and Gene Therapy Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Cell and Gene Therapy Market - Breakup by Therapy Type

6.1 Cell Therapy
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Segmentation
  - 6.1.3.1 Stem Cell
  - 6.1.3.2 Non-Stem Cell
- 6.1.4 Market Forecast (2025-2033)
6.2 Gene Therapy
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)

7 Japan Cell and Gene Therapy Market - Breakup by Indication

7.1 Cardiovascular Disease
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Oncology Disorder
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Genetic Disorder
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Infectious Disease
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Neurological Disorder
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)
7.6 Others
- 7.6.1 Historical and Current Market Trends (2019-2024)
- 7.6.2 Market Forecast (2025-2033)

8 Japan Cell and Gene Therapy Market - Breakup by Delivery Mode

8.1 In-Vivo
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Ex-Vivo
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)

9 Japan Cell and Gene Therapy Market - Breakup by End User

9.1 Hospitals
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2019-2024)
- 9.1.3 Market Forecast (2025-2033)
9.2 Cancer Care Centers
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2019-2024)
- 9.2.3 Market Forecast (2025-2033)
9.3 Pharmaceutical and Biotechnology Companies
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2019-2024)
- 9.3.3 Market Forecast (2025-2033)
9.4 Others
- 9.4.1 Historical and Current Market Trends (2019-2024)
- 9.4.2 Market Forecast (2025-2033)

10 Japan Cell and Gene Therapy Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Product Portfolio
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Product Portfolio
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Product Portfolio
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Product Portfolio
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Product Portfolio
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Cell and Gene Therapy Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis